



**Press Release**

Thursday, August 1, 2013

Strides Arcolab Limited,  
Strides House,  
Bannerghatta Road,  
Bangalore – 560076, India

BSE: 532531  
NSE: STAR

---

## **Strides Arcolab receives ANDA approval from USFDA for Tenofovir Disoproxil Fumarate and Emtricitabine Tablets**

**Approval under the PEPFAR scheme, Total PEPFAR approvals at 20**

---

**August 1, 2013, Bangalore:** Strides Arcolab Limited (BSE: 532531, NSE: STAR) today announced that it has received tentative approval from the US FDA for its anti aids combination drug **Tenofovir Disoproxil Fumarate and Emtricitabine Tablets, 300mg and 200mg.**

The Company is one among the 6 generics company to have received USFDA approval. This abbreviated new drug application (ANDA) has been reviewed under the expedited provisions of the President’s Emergency Plan for AIDS relief (PEPFAR).

The company supplies ARV products to global procurement agencies and this approval adds to the overall basket of medicines available.

### ***About Tenofovir Disoproxil Fumarate and Emtricitabine Tablets***

The combination drug is the generic equivalent of Gilead Sciences Inc’s Truvada Tablets and falls under the anti-retroviral (ARV) segment. It is indicated in combination with other anti-retroviral agents for the treatment of HIV-1 infection in adults.

### **About Strides Arcolab**

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.



The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at [www.stridesarco.com](http://www.stridesarco.com).

For further information, please contact:

<u>Strides</u>	<u>PR Consultancy</u>
Mr. Manish Gupta, CEO - Pharma +91 80 6784 0112	Weber Shandwick
Mr. Kannan N: +91 98450 54745 (Investors)	Kaveri Mandanna: +91 90089 59697 <a href="mailto:KMandanna@webershandwick.com">KMandanna@webershandwick.com</a>
	Mahesh Nair: +91 98803 76648 <a href="mailto:MNair@webershandwick.com">MNair@webershandwick.com</a>

